Metoclopramide Hydrochloride Syri Pharma (Metoclopramide Hydrochloride Anhydrous)

Metoclopramide Hydrochloride is used as an antiemetic and gastro‑prokinetic agent to treat disorders of the upper gastrointestinal tract.

• Nausea and vomiting: Reduces the sensation of nausea and the frequency of vomiting in postoperative, chemotherapy‑induced, and other acute settings.
• Gastroparesis: Enhances gastric motility, facilitating faster gastric emptying in patients with delayed stomach emptying.
• Gastro‑oesophageal reflux disease (GERD): Improves lower esophageal sphincter tone and gastric emptying, helping to control reflux symptoms.

• Metoclopramide Hydrochloride exerts its effect by antagonizing dopamine D2 receptors in the chemoreceptor trigger zone of the brain and in the gastrointestinal tract. This blockade diminishes the central vomiting stimulus and increases the release of acetylcholine in the gut, promoting coordinated smooth‑muscle contractions that accelerate gastric emptying and enhance lower esophageal sphincter pressure. The combined central and peripheral actions result in overall improvement of upper GI motility.

Metoclopramide Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Drowsiness: Feeling of sleepiness or reduced alertness.
• Fatigue: Generalized lack of energy.
• Diarrhea: Loose, watery stools.
• Restlessness: Unexplained agitation or inability to stay still.
• Dry mouth: Reduced salivation leading to a dry sensation in the mouth.
• Headache: Mild to moderate head pain.

Serious or Rare Side Effects

• Extrapyramidal symptoms: Involuntary muscle movements, tremor, or rigidity.
• Tardive dyskinesia: Persistent, irreversible facial or tongue movements with long‑term use.
• Neuroleptic malignant syndrome: Rare life‑threatening reaction with high fever, muscle rigidity, and autonomic instability.

When prescribing Metoclopramide Hydrochloride, clinicians should consider several safety precautions to minimize risks.

• Contraindications: Avoid use in patients with known hypersensitivity to metoclopramide or other dopamine antagonists.
• Neurological disorders: Use cautiously in individuals with Parkinson’s disease, seizure disorders, or a history of extrapyramidal reactions.
• Cardiac conditions: Monitor patients with known cardiac arrhythmias or prolonged QT interval.
• Pregnancy and lactation: Use only if the potential benefit justifies the potential risk, as safety data are limited.
• Drug interactions: Review concomitant medications for potential interactions, especially with other CNS depressants or serotonergic agents.
• Store at ambient temperature: Keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Metoclopramide Hydrochloride can interact with several medicines, altering its efficacy or increasing the risk of adverse effects.

Major Interactions (Avoid)

• Antipsychotics (e.g., haloperidol, chlorpromazine): Combined dopamine blockade can precipitate severe extrapyramidal symptoms.
• Monoamine oxidase inhibitors (MAOIs): May increase the risk of hypertensive crisis and serotonin syndrome.
• Serotonergic agents (e.g., SSRIs, triptans): Heightened potential for serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, opioids): May enhance sedation and drowsiness.
• Anticholinergic drugs (e.g., atropine, scopolamine): Can reduce the pro‑kinetic effect of metoclopramide.
• CYP2D6 inhibitors (e.g., fluoxetine, quinidine): May increase plasma concentrations of metoclopramide.